Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.

MLA

Gökbuget, N., et al. “Blinatumomab vs Historical Standard Therapy of Adult Relapsed/Refractory Acute Lymphoblastic Leukemia.” Blood Cancer Journal, 2016. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1287344751&authtype=sso&custid=ns315887.

APA

Gökbuget, N., Gökbuget, N., Kelsh, M., Chia, V., Advani, A., Bassan, R., Dombret, H., Doubek, M., Fielding, A., Giebel, S., Haddad, V., Hoelzer, D., Holland, C., Ifrah, N., Katz, A., Maniar, T., Martinelli, G., Morgades, M., O’Brien, S., … Kantarjian, H. (2016). Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer Journal.

Chicago

Gökbuget, N, N Gökbuget, M Kelsh, V Chia, A Advani, R Bassan, H Dombret, et al. 2016. “Blinatumomab vs Historical Standard Therapy of Adult Relapsed/Refractory Acute Lymphoblastic Leukemia.” Blood Cancer Journal. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1287344751&authtype=sso&custid=ns315887.